Published in PLoS Negl Trop Dis on October 26, 2010
Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis (2012) 1.41
Leishmaniasis: new insights from an old and neglected disease. Eur J Clin Microbiol Infect Dis (2011) 1.17
Visceral Leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop Dis (2014) 1.09
An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother (2014) 1.03
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem Rev (2014) 1.00
Identification of new antileishmanial leads from hits obtained by high-throughput screening. Antimicrob Agents Chemother (2011) 1.00
Therapeutic options for visceral leishmaniasis. Drugs (2013) 1.00
Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol. PLoS Negl Trop Dis (2012) 0.98
New trends in aminoglycosides use. Medchemcomm (2014) 0.96
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar). Ther Clin Risk Manag (2012) 0.92
Concomitant malaria among visceral leishmaniasis in-patients from Gedarif and Sennar States, Sudan: a retrospective case-control study. BMC Public Health (2013) 0.90
Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya. Am J Trop Med Hyg (2013) 0.90
Drug resistance analysis by next generation sequencing in Leishmania. Int J Parasitol Drugs Drug Resist (2014) 0.87
Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines. Hum Vaccin Immunother (2012) 0.84
Burden of visceral leishmaniasis in villages of eastern Gedaref State, Sudan: an exhaustive cross-sectional survey. PLoS Negl Trop Dis (2012) 0.80
Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis (2016) 0.78
The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis. Trans R Soc Trop Med Hyg (2016) 0.76
Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. J Transl Int Med (2015) 0.76
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. Clin Drug Investig (2017) 0.75
Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review. Clin Pharmacokinet (2016) 0.75
New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas. Drug Dev Res (2011) 0.75
Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance. F1000Res (2016) 0.75
Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med (2004) 11.47
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Leishmaniasis. Public health aspects and control. Clin Dermatol (1997) 4.77
Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med (2007) 3.74
Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg (1983) 2.57
Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ (1998) 2.15
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis (2010) 1.54
Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol (1998) 1.22
Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg (2000) 1.15
Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg (2004) 1.11
Aminoglycoside ototoxicity. Am J Otolaryngol (1986) 0.90
Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects. Antimicrob Agents Chemother (1997) 0.89
WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet (2004) 9.27
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med (2016) 6.22
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
Strengthening capacity for health research in Africa. Lancet (2008) 3.27
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet (2011) 2.81
The impact of HIV/AIDS on labour productivity in Kenya. Trop Med Int Health (2004) 2.76
Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health (2010) 2.62
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother (2012) 2.14
The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination. Parasit Vectors (2012) 1.99
Active trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020? PLoS Negl Trop Dis (2009) 1.96
Combination therapy for visceral leishmaniasis. Lancet Infect Dis (2010) 1.96
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J (2008) 1.91
Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg (2006) 1.91
The role of context: neighbourhood characteristics strongly influence HIV risk in young women in Ndola, Zambia. Trop Med Int Health (2008) 1.89
Chloroquine resistance before and after its withdrawal in Kenya. Malar J (2009) 1.88
Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study. Lancet Neurol (2012) 1.87
Trachoma prevalence and associated risk factors in the gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Negl Trop Dis (2010) 1.81
Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malar J (2006) 1.80
Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials (2006) 1.72
Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS Clin Trials (2006) 1.63
Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers. AIDS (2008) 1.63
A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis (2012) 1.59
Incidence and outcome of convulsive status epilepticus in Kenyan children: a cohort study. Lancet Neurol (2008) 1.55
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis (2010) 1.54
Molecular characterization of human isolates of Giardia duodenalis from Ethiopia. Acta Trop (2007) 1.45
Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis (2012) 1.41
The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Malar J (2008) 1.40
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis (2010) 1.35
A diagnostics platform for the integrated mapping, monitoring, and surveillance of neglected tropical diseases: rationale and target product profiles. PLoS Negl Trop Dis (2012) 1.32
Inference of population structure of Leishmania donovani strains isolated from different Ethiopian visceral leishmaniasis endemic areas. PLoS Negl Trop Dis (2010) 1.31
Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis (2009) 1.29
Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs (2009) 1.23
Further studies on the phlebotomine sandflies of the kala-azar endemic lowlands of Humera-Metema (north-west Ethiopia) with observations on their natural blood meal sources. Parasit Vectors (2010) 1.20
Do the socioeconomic impacts of antiretroviral therapy vary by gender? A longitudinal study of Kenyan agricultural worker employment outcomes. BMC Public Health (2009) 1.20
The impact of mass drug administration and long-lasting insecticidal net distribution on Wuchereria bancrofti infection in humans and mosquitoes: an observational study in northern Uganda. Parasit Vectors (2011) 1.18
Lymphatic filariasis in western Ethiopia with special emphasis on prevalence of Wuchereria bancrofti antigenaemia in and around onchocerciasis endemic areas. Trans R Soc Trop Med Hyg (2011) 1.17
Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg (2010) 1.17
Integrated mapping of lymphatic filariasis and podoconiosis: lessons learnt from Ethiopia. Parasit Vectors (2014) 1.15
Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Negl Trop Dis (2013) 1.14
Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia. Am J Trop Med Hyg (2005) 1.14
A simplified and standardized polymerase chain reaction format for the diagnosis of leishmaniasis. J Infect Dis (2008) 1.14
Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ (2008) 1.11
Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan. Malar J (2005) 1.10
Human intestinal schistosomiasis in communities living near three rivers of jimma town, South Western ethiopia. Ethiop J Health Sci (2011) 1.06
To fully tackle the gang of four, needs-driven R & D is essential. PLoS Med (2006) 1.05
Phlebotomus orientalis sand flies from two geographically distant Ethiopian localities: biology, genetic analyses and susceptibility to Leishmania donovani. PLoS Negl Trop Dis (2013) 1.04
Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopia. PLoS Negl Trop Dis (2013) 1.04
Diagnostic accuracy of a prototype point-of-care test for ocular Chlamydia trachomatis under field conditions in The Gambia and Senegal. PLoS Negl Trop Dis (2011) 1.04
Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya. AIDS Care (2010) 1.03
Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth. BMC Res Notes (2012) 1.02
Evaluation of PCR procedures for detecting and quantifying Leishmania donovani DNA in large numbers of dried human blood samples from a visceral leishmaniasis focus in Northern Ethiopia. BMC Infect Dis (2013) 1.02
Mass treatment with azithromycin for trachoma control: participation clusters in households. PLoS Negl Trop Dis (2010) 1.02
Field evaluation of FD-DAT, rK39 dipstick and KATEX (urine latex agglutination) for diagnosis of visceral leishmaniasis in northwest Ethiopia. Trans R Soc Trop Med Hyg (2007) 1.01
Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol Res (2008) 1.00
Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India. PLoS Negl Trop Dis (2014) 1.00
Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection. PLoS Negl Trop Dis (2013) 0.99
Visceral leishmaniasis: new health tools are needed. PLoS Med (2005) 0.99
Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in Ethiopia. PLoS Negl Trop Dis (2012) 0.99
Clinical and neurophysiologic features of active convulsive epilepsy in rural Kenya: a population-based study. Epilepsia (2010) 0.99
A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother (2006) 0.99
Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Negl Trop Dis (2013) 0.99
A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. PLoS Negl Trop Dis (2013) 0.97
Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis (2014) 0.97
In vitro evaluation of antileishmanial activity and toxicity of essential oils of Artemisia absinthium and Echinops kebericho. Chem Biodivers (2011) 0.96
Outbreak of cutaneous leishmaniasis in Silti woreda, Ethiopia: risk factor assessment and causative agent identification. Trans R Soc Trop Med Hyg (2008) 0.96
Spatial distribution of podoconiosis in relation to environmental factors in Ethiopia: a historical review. PLoS One (2013) 0.95
The impact of community level treatment and preventative interventions on trachoma prevalence in rural Ethiopia. Int J Epidemiol (2008) 0.94
Epidemiology of HIV-1 infection in agricultural plantation residents in Kericho, Kenya: preparation for vaccine feasibility studies. J Acquir Immune Defic Syndr (2006) 0.94
Chemosensitization of Plasmodium falciparum by probenecid in vitro. Antimicrob Agents Chemother (2003) 0.94
Genotyping of human papillomavirus in paraffin embedded cervical tissue samples from women in Ethiopia and the Sudan. J Med Virol (2012) 0.93
Molecular characterization of Cryptosporidium isolates from humans in Ethiopia. Acta Trop (2010) 0.93
Treatment options for second-stage gambiense human African trypanosomiasis. Expert Rev Anti Infect Ther (2014) 0.92
Age-related alteration of arginase activity impacts on severity of leishmaniasis. PLoS Negl Trop Dis (2008) 0.91
Plasmodium infection, anaemia and mosquito net use among school children across different settings in Kenya. Trop Med Int Health (2012) 0.91
Trachoma in Western Equatoria State, Southern Sudan: implications for national control. PLoS Negl Trop Dis (2009) 0.91
Validation of two rapid diagnostic tests for visceral leishmaniasis in Kenya. PLoS Negl Trop Dis (2013) 0.90
Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia. Am J Trop Med Hyg (2011) 0.90